Zobrazeno 1 - 10
of 128
pro vyhledávání: '"Chong-rui Xu"'
Autor:
Shi‐Qi Mei, Jia‐Qi Liu, Zi‐Jian Huang, Wei‐Chi Luo, Ying‐Long Peng, Zhi‐Hong Chen, Yu Deng, Chong‐Rui Xu, Qing Zhou
Publikováno v:
Thoracic Cancer, Vol 15, Iss 14, Pp 1119-1131 (2024)
Abstract Background Tertiary lymphoid structures (TLSs) affect the prognosis and efficacy of immunotherapy in patients with non‐small cell lung cancer (NSCLC), but the underlying mechanisms are not well understood. Methods TLSs were identified and
Externí odkaz:
https://doaj.org/article/91b5e8e7ca2245b68edf0333eb0444de
Autor:
Wei-Chi Luo, Shi-Qi Mei, Zi-Jian Huang, Zhi-Hong Chen, Yi-Chen Zhang, Ming-Yi Yang, Jia-Qi Liu, Jing-Yan Xu, Xiao-Rong Yang, Ri-Wei Zhong, Li-Bo Tang, Lin-Xi Yin, Yu Deng, Ying-Long Peng, Chang Lu, Bao-Long Chen, Dong-Xian Ke, Hai-Yan Tu, Jin-Ji Yang, Chong-Rui Xu, Yi-Long Wu, Qing Zhou
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background The effects of gut microbiota and metabolites on the responses to immune checkpoint inhibitors (ICIs) in advanced epidermal growth factor receptor (EGFR) wild-type non-small cell lung cancer (NSCLC) have been studied. However, the
Externí odkaz:
https://doaj.org/article/09696509dfd34aa9a776fab02e6b047a
Autor:
Jun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin, Mei-Mei Fang, Xiao Xiao, Yi-Chen Zhang, Xu-Chao Zhang, Jian Su, Chong-Rui Xu, Hong-Hong Yan, Hua-Jun Chen, Yi-Long Wu, Jin-Ji Yang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Mesenchymal–epithelial transition ( MET ) amplification is a crucial oncogenic driver and a resistance mechanism to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) of non-small-cell lung cancer (NSCLC). Fluorescence i
Externí odkaz:
https://doaj.org/article/0ef134b3e84a4a9f9ebf044f8db4c295
Autor:
Hai‐Yan Tu, Kai Yin, Xiaotian Zhao, E‐E Ke, Si‐Pei Wu, Yang‐Si Li, Mei‐Mei Zheng, Si‐Yang Maggie Liu, Chong‐Rui Xu, Yue‐Li Sun, Jia‐Xin Lin, Xiao‐Yan Bai, Yi‐Chen Zhang, Qing Zhou, Jin‐Ji Yang, Wen‐Zhao Zhong, Bing‐Chao Wang, Xu‐Chao Zhang, Dongqin Zhu, Lingling Yang, Qiuxiang Ou, Yi‐Long Wu
Publikováno v:
Molecular Oncology, Vol 17, Iss 8, Pp 1581-1594 (2023)
The efficacy of immunotherapy in advanced HER2‐mutated non‐small‐cell lung cancer (NSCLC) remains incomprehensively studied. A total of 107 NSCLC patients with de novo HER2 mutations were retrospectively studied at Guangdong Lung Cancer Institu
Externí odkaz:
https://doaj.org/article/d5aadd22e14b45079cd59c661d0f474c
Autor:
Si-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, Yingying Du, Jiu-Wei Cui, Qian Chu, Bing-Fei Xu, Ming-Ying Zheng, Jia-Yi Deng, Chang Lu, Xue-Wu Wei, Yang-Si Li, Mei-Mei Zheng, Ming-Yi Yang, Jie Huang, Anna Li, Xiao-Yan Bai, Yue-Li Sun, Chong-Rui Xu, Bin-Chao Wang, Hua-Jun Chen, Jin-Ji Yang, Hong-Hong Yan, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu
Publikováno v:
EClinicalMedicine, Vol 64, Iss , Pp 102238- (2023)
Summary: Background: Central nervous system (CNS) metastases is inevitable for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). AZD3759 is a novel EGFR-TKI with impressive CNS penetration. Methods: We initiated a pha
Externí odkaz:
https://doaj.org/article/76e8bbf8e79f4c32b3813a7376923f8f
Autor:
Ying-Long Peng, Zi-Yan Wang, Ri-Wei Zhong, Shi-Qi Mei, Jia-Qi Liu, Li-Bo Tang, Zhi Guo, Zi-Rui Ren, Lv Wu, Yu Deng, Zhi-Hong Chen, Qing Zhou, Chong-Rui Xu
Publikováno v:
Cancers, Vol 16, Iss 2, p 304 (2024)
Background: COVID-19 has been ravaging the globe for more than three years. Due to systemic immunosuppression of anti-tumor therapy, application of chemotherapy and adverse effects of surgery, the short- and long-term prognosis of cancer patients to
Externí odkaz:
https://doaj.org/article/cc1768d7aa5b4572b762be3ad56357b1
Autor:
Lingling Yang, Qing Zhou, Jian Su, Yi-Long Wu, Zhi-Hong Chen, Wen-zhao Zhong, Hong-Hong Yan, Qing Gou, Xue-Wu Wei, Xiao-Rong Yang, Jia-Yi Deng, Ming-Yi Yang, Jia-Qi Liu, Chong-Rui Xu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background The liver is a frequent site of metastases and liver metastases (LM) correlate with diminished immunotherapy efficacy in non-small cell lung cancer (NSCLC). This study aimed to analyze whether tumor response to immunotherapy differs betwee
Externí odkaz:
https://doaj.org/article/c3eaf6216ed14b64ba12a48c53dbf0e0
Autor:
Xue-Wu Wei, Chang Lu, Yi-Chen Zhang, Xue Fan, Chong-Rui Xu, Zhi-Hong Chen, Fen Wang, Xiao-Rong Yang, Jia-Yi Deng, Ming-Yi Yang, Qing Gou, Shi-Qi Mei, Wei-Chi Luo, Ri-Wei Zhong, Wen-Zhao Zhong, Jin-Ji Yang, Xu-Chao Zhang, Hai-Yan Tu, Yi-Long Wu, Qing Zhou
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTMetabolism reprogramming within the tumor microenvironment (TME) can have a profound impact on immune cells. Identifying the association between metabolic phenotypes and immune cells in lung adenocarcinoma (LUAD) may reveal mechanisms of resi
Externí odkaz:
https://doaj.org/article/69ff1c8e561c44988808d82daaa7d78f
Autor:
Mei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, Hao Sun, Kai Yin, Ben-Yuan Jiang, Jin-Ji Yang, Xu-Chao Zhang, Qing Zhou, Chong-Rui Xu, Zhen Wang, Hua-Jun Chen, De-Xiang Zhou, Yi-Long Wu
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-12 (2022)
Abstract Background Despite the reported efficacy of osimertinib, central nervous system (CNS) progression is still frequent in EGFR-mutated NSCLC. This study aimed to reveal site-specific resistant mechanisms to osimertinib and investigate subsequen
Externí odkaz:
https://doaj.org/article/ff49dc0b1e09455f9e43b69ece66e951
Autor:
Xue-Wu Wei, MD, Jia-Yi Deng, MD, Chong-Rui Xu, PhD, Zhi-Hong Chen, MD, Dong-Qin Zhu, PhD, Qian Wu, PhD, Xu-Chao Zhang, PhD, Yi-Long Wu, MD, Qing Zhou, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 7, Pp 100348- (2022)
Introduction: BRAF variants were reported resistant mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC. Nevertheless, characteristics and subsequent treatment strategies of such patients remain unclear. Methods: From October 20
Externí odkaz:
https://doaj.org/article/e2a7f95b2eeb404faa818a929575eae9